JUŚKIEWICZ, Adam, GRELEWICZ, Olga, KUCY, Natalia, SERVAAS, Elwira, HABER, Mateusz, KULA, Paula, CZACHOR, Adrianna and KOTULA, Alicja. The Link Between Gut Microbiota and Depression: Exploring the Correlation. Journal of Education, Health and Sport. 2025;77:55276. eISSN 2391-8306.
https://doi.org/10.12775/JEHS.2025.77.55276
https://apcz.umk.pl/JEHS/article/view/55276

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 19.09.2024. Revised: 10.01.2025. Accepted: 20.01.2025. Published: 03.02.2025.

The Link Between Gut Microbiota and Depression: Exploring the Correlation

Adam Juśkiewicz*

National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, 02-507 Warszawa

ad.juskiewicz@gmail.com

https://orcid.org/0000-0001-9884-3513

Olga Grelewicz

National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, 02-507 Warszawa

olga.grelewicz@gmail.com

https://orcid.org/0000-0001-5738-9262

Natalia Kucy
Infant Jesus Clinical Hospital UCC MUW,
Lindleya 4, 02-005 Warszawa
tusia.noelle@icloud.com
https://orcid.org/0009-0007-5468-6289

Elwira Servaas
National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, 02-507 Warszawa
servaaselwira@gmail.com
https://orcid.org/0009-0004-8432-7824

Mateusz Haber
Central Clinical Hospital in Warsaw
Banacha 1a, 02-097, Warszawa
mhaber.mateusz@gmail.com
https://orcid.org/0009-0002-8441-4931

Paula Kula
Central Clinical Hospital in Warsaw,
Banacha 1a, 02-097, Warszawa
paulakula98@gmail.com
https://orcid.org/0009-0004-7503-2602

Adrianna Czachor
Infant Jesus Clinical Hospital UCC MUW,
Lindleya 4, 02-005 Warszawa
adriannaczachor@gmail.com
https://orcid.org/0009-0001-8596-9341

Alicja Kotula
Infant Jesus Clinical Hospital UCC MUW,
Lindleya 4, 02-005 Warszawa
kotulaalicja5@gmail.com
https://orcid.org/0009-0008-9718-1667

*corresponding author: Adam Juśkiewicz, e-mail: ad.juskiewicz@gmail.com

Abstract

Introduction: Depression represents a significant global health challenge, affecting approximately 4.4% of the global population and ranking as the leading cause of disability worldwide. Despite advancements in pharmacotherapy and psychotherapeutic interventions, a substantial proportion of individuals with depression experience treatment resistance, recurrence of symptoms, or inadequate response to standard treatments.

Aim of the Study: This review explores the emerging role of the gut microbiome in depression, focusing on its potential as a therapeutic target.

Materials and Methods: A comprehensive literature search was conducted using electronic databases including PubMed/MEDLINE and Google Scholar. The search encompassed articles utilizing keywords and Medical Subject Headings (MeSH) terms related to "gut microbiome," "depression," "microbiota-gut-brain axis," "psychiatric disorders," and "clinical studies."

Conclusion: Therapeutic strategies targeting the gut microbiota offer promising avenues for alleviating depressive symptoms and enhancing treatment outcomes. Probiotics, prebiotics, dietary modifications, and fecal microbiota transplantation (FMT) represent diverse interventions aimed at restoring microbial balance, modulating gut-brain communication, and reducing neuroinflammation associated with depression. Further research is needed to optimize therapeutic approaches, explore personalized medicine strategies based on individual microbiome profiles and clarify the safety and efficacy of microbial-based therapies in clinical settings.

Keywords: Gut microbiome, Depression, Microbiota-gut-brain axis, Psychiatric disorders, Probiotics, Fecal microbiota transplantation (FMT)

Introduction

Depression represents a pervasive global health challenge, affecting approximately 4.4% of the global population and ranking as the leading cause of disability worldwide [1]. Despite advancements in pharmacotherapy and psychotherapeutic interventions, a substantial proportion of individuals with depression experience treatment resistance, recurrence of symptoms, or inadequate response to standard treatments [2]. This clinical complexity underscores the need for innovative therapeutic strategies that target novel pathways implicated in the pathophysiology of depressive disorders.

Recent research has increasingly implicated the gut microbiota in the pathophysiology of depression, highlighting its potential as a therapeutic target. Studies have shown that alterations in gut microbial composition, characterized by reduced diversity and dysbiosis, are associated with higher prevalence and severity of depressive symptoms [8, 9]. Mechanistically, these changes can influence brain function through the gut-brain axis, affecting neurotransmitter pathways, neuroinflammation, and stress response systems [7, 9].

Neuroinflammation, a hallmark of various neurodegenerative and psychiatric disorders, has been increasingly linked to the gut microbiota through the gut-brain axis. Recent research indicates that dysbiosis, or an imbalance in the gut microbiota, can contribute to neuroinflammation by altering the permeability of the gut barrier, leading to the translocation of bacteria and endotoxins such as lipopolysaccharides (LPS) into the bloodstream. This, in turn, triggers systemic inflammation and the activation of microglia, the resident immune cells of the central nervous system (CNS) [26, 27]. Animal studies have demonstrated that specific gut microbiota compositions can either exacerbate or ameliorate neuroinflammatory responses. For instance, mice treated with antibiotics to alter their gut microbiota showed reduced neuroinflammation and improved outcomes in models of multiple sclerosis (MS) and Alzheimer's disease (AD) [28, 29]. Moreover, probiotic administration has been shown to decrease pro-inflammatory cytokine levels and modulate microglial activity, suggesting a potential therapeutic role for microbiota-targeted interventions in neuroinflammatory conditions [30, 31]. Clinical studies have also found correlations between gut microbiota composition and biomarkers of neuroinflammation in patients with major depressive disorder (MDD) and autism spectrum disorder (ASD), further supporting the gut-brain connection in neuroinflammatory processes [8, 32]. Despite these advances, the precise mechanisms by which gut microbiota influence neuroinflammation remain to be fully elucidated, necessitating further

research to explore microbial-derived metabolites and their effects on CNS immune responses [7, 33].

In recent years, research has increasingly focused on the bidirectional communication between the gut microbiome and the central nervous system (CNS) as a potential modulator of mood and behavior.

The bidirectional communication between the gut microbiome and the central nervous system (CNS) has emerged as a critical area of interest in understanding the pathophysiology of various psychiatric disorders, particularly depression. This complex interaction, often referred to as the gut-brain axis, encompasses multiple pathways, including neural, endocrine, immune, and metabolic routes. Research highlights that the gut microbiome influences brain function and behavior through the production of neuroactive substances, modulation of systemic and central immune responses, and the regulation of the hypothalamic-pituitary-adrenal (HPA) axis [3, 11]. For instance, germ-free animal models have shown altered stress responses and behavioral changes, underscoring the role of gut microbiota in modulating CNS functions [5]. Moreover, specific bacterial strains, such as Bifidobacterium and Lactobacillus, have demonstrated anxiolytic and antidepressant-like effects, likely mediated through vagal nerve pathways and the modulation of neurotransmitter levels, including serotonin and gamma-aminobutyric acid (GABA) [6, 7]. Clinical studies have also established a link between dysbiosis—an imbalance in the gut microbial community—and depressive disorders, with alterations in gut microbiota composition being associated with increased inflammation, altered metabolic profiles, and disrupted gut barrier integrity [4, 8]. Additionally, interventions aimed at modifying the gut microbiota, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), have shown promise in alleviating depressive symptoms and improving overall mental health, further supporting the therapeutic potential of targeting the gut-brain axis in psychiatric care [12, 13].

The gut microbiome, comprising a diverse community of microorganisms inhabiting the gastrointestinal tract, plays a pivotal role in maintaining host homeostasis and influencing various physiological processes, including immune function, metabolism, and neurodevelopment [3]. Importantly, emerging evidence suggests that dysbiosis, characterized by alterations in the composition, diversity, and metabolic activity of gut microbiota, may contribute to the pathogenesis of psychiatric disorders, including depression [4].

Preclinical studies utilizing germ-free animal models and microbiota transplantation techniques have provided compelling insights into the role of the gut microbiome in regulating stress responses, emotional behavior, and mood-related neurotransmitter pathways [5, 6]. These studies underscore the intricate mechanisms through which gut microbial communities interact with the host's immune system, neuroendocrine system, and neural circuits along the gut-brain axis, influencing emotional and cognitive processes [7].

Clinical investigations have also begun to elucidate associations between gut microbiome alterations and depressive symptoms in human populations. Studies utilizing metagenomic sequencing and advanced molecular techniques have identified specific microbial signatures associated with depressive disorders, implicating potential biomarkers and mechanistic pathways underlying microbiota-brain interactions [8, 9]. Moreover, longitudinal cohort studies have highlighted correlations between gut microbiome composition, inflammatory markers, and treatment outcomes in individuals with depression, suggesting a role for microbiota-targeted interventions in psychiatric care [10, 11].

Methods

A comprehensive literature search was conducted using electronic databases including PubMed/MEDLINE and Google Scholar. The search strategy encompassed articles utilizing keywords and Medical Subject Headings (MeSH) terms related to "gut microbiome," "depression," "microbiota-gut-brain axis," "psychiatric disorders," and "clinical studies." The search was restricted to studies published in English. Additionally, reference lists of identified articles and relevant reviews were manually screened for additional studies.

Studies eligible for inclusion in this review were randomized controlled trials, observational studies, meta-analyses, systematic reviews, and relevant clinical practice guidelines evaluating the association between gut microbiome composition and depressive symptoms. Priority was given to studies reporting on mechanisms of microbiota-brain interactions, clinical implications for depression management, and potential microbiome-based therapeutic strategies.

This review aims to comprehensively evaluate the current literature on the influence of the gut microbiome on depression prevalence. It will synthesize findings from preclinical models and clinical studies to elucidate the mechanisms by which gut microbial communities impact mood regulation and the pathophysiology of depressive disorders. Furthermore, it will

discuss the potential implications for developing microbiome-based therapeutic strategies aimed at enhancing treatment efficacy and personalized management approaches in psychiatry.

Results

Therapeutic interventions targeting the gut microbiota have garnered attention for their potential to alleviate depressive symptoms. Probiotics, such as strains of Lactobacillus and Bifidobacterium, have shown promise in clinical trials for their ability to modulate mood and reduce depressive symptoms [12, 13]. They act through various mechanisms, including the production of neurotransmitters like serotonin, regulation of neuroinflammation, and enhancement of gut barrier function [12, 13].

Prebiotics, dietary fibers that promote the growth of beneficial gut bacteria, have also been explored for their potential antidepressant effects. By fostering the growth of Bifidobacteria and Lactobacilli, prebiotics contribute to the production of short-chain fatty acids (SCFAs) like butyrate, which are known to influence brain function and behavior via the gut-brain axis [17, 18]. Meta-analyses support the efficacy of dietary interventions, such as the Mediterranean diet, which enhances microbial diversity and reduces inflammation, thereby improving mood and mitigating depressive symptoms [19].

Fecal microbiota transplantation (FMT) is increasingly recognized for its potential therapeutic role in psychiatric disorders, underpinned by the emerging concept of the gut-brain axis. This bi-directional communication network between the gastrointestinal tract and the central nervous system suggests that the gut microbiota can influence brain function and behavior. Recent studies have explored the impact of FMT on conditions such as depression, anxiety, and autism spectrum disorder (ASD). In animal models, FMT from donors with specific mental health conditions to germ-free mice has resulted in the recipients exhibiting similar behavioral changes, indicating a causal relationship between gut microbiota and psychiatric symptoms [32, 34]. Another study on patients with ASD reported improvements in behavioral symptoms and gastrointestinal issues following FMT, suggesting a link between gut microbiota modulation and symptom alleviation [32]. Despite these promising findings, the exact mechanisms by which FMT exerts its effects on mental health remain largely speculative, necessitating further research to elucidate the pathways involved and to optimize treatment protocols for clinical use [7, 35].

Discussion

The burgeoning field of research exploring the bidirectional communication between the gut microbiota and the brain has significantly advanced our understanding of the potential mechanisms underlying depression. Accumulating evidence suggests that alterations in gut microbial composition and function contribute to the pathophysiology of depression through various pathways, including immune activation, neuroendocrine alterations, and modulation of neurotransmitter systems [7, 8]. The concept of the gut-brain axis, whereby microbial metabolites and signaling molecules influence neural function and behavior, underscores the complexity of this relationship [9].

Therapeutic interventions targeting the gut microbiota, such as probiotics, prebiotics, dietary modifications, and fecal microbiota transplantation (FMT), offer promising strategies for managing depressive symptoms. Probiotics, particularly strains of Lactobacillus and Bifidobacterium, have shown efficacy in alleviating depressive symptoms, possibly by producing neurotransmitters like serotonin and regulating neuroinflammation [12, 13]. Prebiotics, by promoting the growth of beneficial gut bacteria and enhancing the production of short-chain fatty acids, also hold potential as adjunctive treatments for depression [17, 18]. Moreover, dietary interventions, including the Mediterranean diet, which promotes microbial diversity and anti-inflammatory effects, have demonstrated beneficial effects on mood and depressive symptoms [19].

Despite these promising findings, several challenges and avenues for future research remain. The heterogeneity of study designs, microbial interventions, and patient populations complicates direct comparisons and generalizability of results. Further large-scale, well-controlled clinical trials are warranted to establish the optimal dose, duration, and formulation of microbial-based therapies. Additionally, understanding the individualized response to these interventions based on gut microbial profiles, genetic predispositions, and environmental factors will be crucial for personalized medicine approaches in depression treatment.

Conclusion

The exploration of the gut microbiome's influence on depression represents a pivotal advancement in psychiatric research, revealing complex interactions between microbial communities and the central nervous system. Mounting evidence underscores that dysbiosis, characterized by disruptions in gut microbial composition and function, contributes

significantly to the pathogenesis of depressive disorders. These disturbances affect multiple physiological systems, including immune function, neuroendocrine signaling, and neurotransmitter pathways, thereby influencing mood regulation and emotional well-being through the gut-brain axis.

Therapeutic strategies targeting the gut microbiome offer promising avenues for alleviating depressive symptoms and enhancing treatment outcomes. Probiotics, particularly strains of Lactobacillus and Bifidobacterium, have emerged as frontrunners in clinical trials for their ability to modulate mood and reduce depressive symptoms. Mechanistically, probiotics may exert beneficial effects through the production of neurotransmitters like serotonin, regulation of neuroinflammatory responses, and enhancement of gut barrier function, thereby improving overall mental health [7, 20].

In parallel, prebiotics—dietary fibers that foster the growth of beneficial gut bacteria—have demonstrated potential as complementary treatments for depression. By promoting the production of short-chain fatty acids (SCFAs) like butyrate, prebiotics contribute to gut microbial diversity and metabolic stability, influencing brain function and behavior via microbial metabolites and immune modulation [9, 21].

Moreover, dietary interventions such as the Mediterranean diet, rich in fruits, vegetables, and whole grains, have shown robust associations with improved mental health outcomes. This dietary pattern supports microbial diversity, reduces systemic inflammation, and enhances antioxidant defenses, all of which contribute to mood stabilization and resilience against depressive symptoms [13, 12].

Excitingly, fecal microbiota transplantation (FMT) represents a pioneering approach in microbiome-based therapies, demonstrating early promise in restoring gut microbial balance and alleviating depression symptoms in preliminary studies [17, 18]. While further research is necessary to refine FMT protocols and establish long-term safety and efficacy, its potential to recalibrate dysbiotic gut microbiota holds significant implications for refractory depression and treatment-resistant cases.

However, translating microbiome-based therapies from bench to bedside necessitates overcoming several challenges. Variability in study methodologies, microbial interventions, and patient heterogeneity complicates direct comparisons and generalizability of results.

Rigorous, well-controlled clinical trials are essential to elucidate optimal treatment modalities, dosing regimens, and long-term impacts of microbial interventions on depressive symptomatology [22, 23].

Personalized medicine approaches tailored to individual gut microbial profiles, genetic susceptibilities, and environmental influences represent the future frontier of depression treatment. Integrating advanced molecular diagnostics and bioinformatics will enable clinicians to predict treatment responses and optimize therapeutic outcomes, paving the way for precision psychiatry in the era of microbiome-driven medicine [24, 25].

In conclusion, while the gut microbiome's role in depression is increasingly recognized, continued interdisciplinary collaboration and rigorous scientific inquiry are imperative. Future research endeavors should focus on unraveling specific microbial mechanisms, refining therapeutic strategies, and advancing personalized interventions to optimize mental health outcomes and quality of life for individuals affected by depression.

Authors contribution:

Conceptualization: Adam Juśkiewicz, Olga Grelewicz,
methodology: Adrianna Czachor;
software: Mateusz Haber;
check: Natalia Kucy, Paula Kula, Elwira Servaas;
formal analysis: Alicja Kotula;
investigation: Elwira Servaas;
resources: Paula Kula;
data curation: Adrianna Czachor;
writing - rough preparation: Adam Juśkiewicz;
writing - review and editing: Natalia Kucy;
visualization: Mateusz Haber;
supervision: Alicja Kotula;
project administration: Olga Grelewicz.
All authors have read and agreed with the published version of the manuscript.

Conflict of interest: The authors declare no conflict of interest.

Funding:This review has not received any external funding.

Statement of institutional review committee: not applicable

Informed consent: not applicable

Data availability: not applicable

Acknowledgments: not applicable

References

1. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. WHO Press; 2017. Available at: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf
2. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. The American journal of psychiatry, 2006;163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
3. Mayer, E. A., Knight, R., Mazmanian, S. K., Cryan, J. F., & Tillisch, K. Gut microbes and the brain: paradigm shift in neuroscience. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014;34(46), 15490–15496. https://doi.org/10.1523/JNEUROSCI.3299-14.2014
4. Kelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J., Beers, S., Scott, K., Moloney, G., Hoban, A. E., Scott, L., Fitzgerald, P., Ross, P., Stanton, C., Clarke, G., Cryan, J. F., & Dinan, T. G. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. Journal of psychiatric research, 2016;82, 109–118. https://doi.org/10.1016/j.jpsychires.2016.07.019
5. Sudo N, Chida Y, Aiba Y, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004;558(Pt 1):263-275. doi:10.1113/jphysiol.2004.063388
6. Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X. N., Kubo, C., & Koga, Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system

for stress response in mice. The Journal of physiology, 2004;558(Pt 1), 263–275. https://doi.org/10.1113/jphysiol.2004.063388

7. Cryan, J. F., & Dinan, T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature reviews. Neuroscience, 2012;13(10), 701–712. https://doi.org/10.1038/nrn3346
8. Jiang, H., Ling, Z., Zhang, Y., Mao, H., Ma, Z., Yin, Y., Wang, W., Tang, W., Tan, Z., Shi, J., Li, L., & Ruan, B. Altered fecal microbiota composition in patients with major depressive disorder. Brain, behavior, and immunity, 2015;48, 186–194. https://doi.org/10.1016/j.bbi.2015.03.016
9. Zheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., Zeng, L., Chen, J., Fan, S., Du, X., Zhang, X., Yang, D., Yang, Y., Meng, H., Li, W., Melgiri, N. D., Licinio, J., Wei, H., & Xie, P. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Molecular psychiatry, 2016;21(6), 786–796. https://doi.org/10.1038/mp.2016.44
10. Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y., Schiweck, C., Kurilshikov, A., Joossens, M., Wijmenga, C., Claes, S., Van Oudenhove, L., Zhernakova, A., Vieira-Silva, S., & Raes, J. The neuroactive potential of the human gut microbiota in quality of life and depression. Nature microbiology, 2019;4(4), 623–632.https://doi.org/10.1038/s41564-018-0337-x
11. Foster, J. A., & McVey Neufeld, K. A. Gut-brain axis: how the microbiome influences anxiety and depression. Trends in neurosciences, 2013;36(5), 305–312. https://doi.org/10.1016/j.tins.2013.01.005
12. Wallace, C. J. K., & Milev, R. The effects of probiotics on depressive symptoms in humans: a systematic review. Annals of general psychiatry, 2017;16, 14. https://doi.org/10.1186/s12991-017-0138-2
13. Ng, Q. X., Peters, C., Ho, C. Y. X., Lim, D. Y., & Yeo, W. S. A meta-analysis of the use of probiotics to alleviate depressive symptoms. Journal of affective disorders, 2018;228, 13–19. https://doi.org/10.1016/j.jad.2017.11.063
14. Liu, R. T., Walsh, R. F. L., & Sheehan, A. E. Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials. Neuroscience and biobehavioral reviews, 2019;102, 13–23. https://doi.org/10.1016/j.neubiorev.2019.03.023

15. Dinan, T. G., Stanton, C., & Cryan, J. F. Psychobiotics: a novel class of psychotropic. Biological psychiatry, 2013;74(10), 720–726. https://doi.org/10.1016/j.biopsych.2013.05.001
16. Schmidt, K., Cowen, P. J., Harmer, C. J., Tzortzis, G., Errington, S., & Burnet, P. W. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology, 2015;232(10), 1793–1801. https://doi.org/10.1007/s00213-014-3810-0
17. Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., & Vinderola, G. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nature reviews. Gastroenterology & hepatology, 2021;18(9), 649–667. https://doi.org/10.1038/s41575-021-00440-6
18. Lassale, C., Batty, G. D., Baghdadli, A., Jacka, F., Sánchez-Villegas, A., Kivimäki, M., & Akbaraly, T. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. Molecular psychiatry, 2019;24(7), 965–986. https://doi.org/10.1038/s41380-018-0237-8
19. Parletta, N., Zarnowiecki, D., Cho, J., Wilson, A., Bogomolova, S., Villani, A., Itsiopoulos, C., Niyonsenga, T., Blunden, S., Meyer, B., Segal, L., Baune, B. T., & O'Dea, K. A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: A randomized controlled trial (HELFIMED). Nutritional neuroscience, 2019;22(7), 474–487. https://doi.org/10.1080/1028415X.2017.1411320
20. Kelly, J. R., Kennedy, P. J., Cryan, J. F., Dinan, T. G., Clarke, G., & Hyland, N. P. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Frontiers in cellular neuroscience, 2015;9, 392. https://doi.org/10.3389/fncel.2015.00392
21. Sarkar, A., Lehto, S. M., Harty, S., Dinan, T. G., Cryan, J. F., & Burnet, P. W. J. (2016). Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals. Trends in neurosciences, 2016;39(11), 763–781. https://doi.org/10.1016/j.tins.2016.09.002
22. Kurokawa, S., Kishimoto, T., Mizuno, S., Masaoka, T., Naganuma, M., Liang, K. C., Kitazawa, M., Nakashima, M., Shindo, C., Suda, W., Hattori, M., Kanai, T., & Mimura, M. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation:

An open-label observational study. Journal of affective disorders, 2018;235, 506–512. https://doi.org/10.1016/j.jad.2018.04.038

23. Rieder, R., Wisniewski, P. J., Alderman, B. L., & Campbell, S. C. Microbes and mental health: A review. Brain, behavior, and immunity, 2017;66, 9–17. https://doi.org/10.1016/j.bbi.2017.01.016
24. Jacka, F. N., O'Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M. L., Brazionis, L., Dean, O. M., Hodge, A. M., & Berk, M. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC medicine, 2017;15(1), 23. https://doi.org/10.1186/s12916-017-0791-y
25. Dash, S., Clarke, G., Berk, M., & Jacka, F. N. The gut microbiome and diet in psychiatry: focus on depression. Current opinion in psychiatry, 2015;28(1), 1–6. https://doi.org/10.1097/YCO.0000000000000117
26. Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., Schwierzeck, V., Utermöhlen, O., Chun, E., Garrett, W. S., McCoy, K. D., Diefenbach, A., Staeheli, P., Stecher, B., Amit, I., & Prinz, M. Host microbiota constantly control maturation and function of microglia in the CNS. Nature neuroscience, 2015;18(7), 965–977. https://doi.org/10.1038/nn.4030
27. Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. The Central Nervous System and the Gut Microbiome. Cell, 2016;167(4), 915–932. https://doi.org/10.1016/j.cell.2016.10.027
28. Minter, M. R., Hinterleitner, R., Meisel, M., Zhang, C., Leone, V., Zhang, X., Oyler-Castrillo, P., Zhang, X., Musch, M. W., Shen, X., Jabri, B., Chang, E. B., Tanzi, R. E., & Sisodia, S. S. Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE/PS1ΔE9 murine model of Alzheimer's disease. Scientific reports, 2017;7(1), 10411. https://doi.org/10.1038/s41598-017-11047-w
29. Ochoa-Repáraz, J., Mielcarz, D. W., Ditrio, L. E., Burroughs, A. R., Foureau, D. M., Haque-Begum, S., & Kasper, L. H. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950), 2009;183(10), 6041–6050. https://doi.org/10.4049/jimmunol.0900747

30. Ait-Belgnaoui, A., Colom, A., Braniste, V., Ramalho, L., Marrot, A., Cartier, C., Houdeau, E., Theodorou, V., & Tompkins, T. Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice. Neurogastroenterology and motility, 2014;26(4), 510–520. https://doi.org/10.1111/nmo.12295
31. Wang, Y., & Kasper, L. H. The role of microbiome in central nervous system disorders. Brain, behavior, and immunity, 2014;38, 1–12. https://doi.org/10.1016/j.bbi.2013.12.015
32. Kang, D. W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., Pollard, E. L., Roux, S., Sadowsky, M. J., Lipson, K. S., Sullivan, M. B., Caporaso, J. G., & Krajmalnik-Brown, R. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome, 2017;5(1), 10. https://doi.org/10.1186/s40168-016-0225-7
33. Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nature reviews. Gastroenterology & hepatology, 2019;16(8), 461–478. https://doi.org/10.1038/s41575-019-0157-3
34. Zheng, P., Zeng, B., Liu, M., Chen, J., Pan, J., Han, Y., Liu, Y., Cheng, K., Zhou, C., Wang, H., Zhou, X., Gui, S., Perry, S. W., Wong, M. L., Licinio, J., Wei, H., & Xie, P. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Science advances, 2019;5(2), eaau8317. https://doi.org/10.1126/sciadv.aau8317
35. Rea, K., Dinan, T. G., & Cryan, J. F. The microbiome: A key regulator of stress and neuroinflammation. Neurobiology of stress, 2016;4, 23–33. https://doi.org/10.1016/j.ynstr.2016.03.001